Evidence map›Paper›PMID 39273069›Full record

ArticleCells2024

Dysregulation of miR-223, miR-146a, and miR-193a Expression Profile in Acute and Chronic Phases of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice.

Saba Gharibi, Bahram Moghimi, Mohammad Bagher Mahmoudi, Ensieh Shahvazian, Ehsan Farashahi Yazd, Maryam Yadegari, Mohammad Taher Tahoori, Esmaeil Yazdanpanah, Dariush Haghmorad, Valentyn Oksenych

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Interleukin 15 and autoimmune disorders: pathophysiology, therapeutic potential, and clinical implications.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Saba GharibiInstitute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University 1 Gheringhap Street, Geelong, VIC 3220, Australia.
Bahram MoghimiDepartment of Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Mohammad Bagher MahmoudiResearch and Development Department, ROJETechnologies, Yazd, Iran.
Ensieh ShahvazianResearch and Development Department, ROJETechnologies, Yazd, Iran.
Ehsan Farashahi YazdDepartment of Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Maryam YadegariDepartment of Biology and Anatomical Sciences, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Mohammad Taher TahooriDepartment of Immunology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Esmaeil YazdanpanahDepartment of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
Dariush HaghmoradDepartment of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran.ORCID 0000-0002-9876-4943
Valentyn OksenychBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway.ORCID 0000-0002-5088-3791

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disease with an unknown etiology. The purpose of this research was to assess miR-223, miR-146a, and miR-193a in acute and chronic phases of experimental autoimmune encephalomyelitis (EAE) mice to consider the possible role of these genes in the pathogenesis of MS. EAE induction was given by myelin oligodendrocyte glycoprotein peptide on female C57BL/6 mice. Clinical scores and other criteria were followed daily until day 21 for the acute group and day 77 for the chronic group. At the end of the course, inflammation and demyelination of the central nervous system (CNS) were assessed by histological analysis. MicroRNA expression levels were assessed by real-time PCR. EAE development attenuated in the chronic group, and histological analysis showed less infiltration and demyelination in the chronic group compared to the acute group. The upper expression of miR-223 is demonstrated in the acute phase of EAE. Moreover, the expression levels of miR-146a and miR-193a decreased in the chronic phase of EAE. MiR-223 showed a highly coordinated elevation in the acute phase both in vivo and in vitro. MiR-146a shares a pathway with miR-223 through effecting IL-6 expression. Further studies are needed to reveal their impact on EAE and possible applications as drug targets and biomarkers.

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalMice, Inbred C57BLMicroRNAsAcute DiseaseAnimalsChronic DiseaseFemaleGene Expression RegulationMiceMultiple SclerosisMicroRNAsMirn146 microRNA, mouseMIRN193 microRNA, mouseMIRN223 microRNA, mouseacute phasechronic phaseEAEMiR-146aMiR-193aMiR-223multiple sclerosis

Identifiers

PMID39273069
PMCPMC11393975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.